Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study

Claudia Allemani(Cancer Research UK), Bernard Rachet(Cancer Research UK), Hannah K. Weir(Centers for Disease Control and Prevention), Lisa C. Richardson(Centers for Disease Control and Prevention), Côme Lepage, Jean Faivre, Gemma Gatta(Fondazione IRCCS Istituto Nazionale dei Tumori), Riccardo Capocaccia, Milena Sant(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Baili(Fondazione IRCCS Istituto Nazionale dei Tumori), Claudio Lombardo(Alleanza Contro il Cancro), Tiiu Aareleid(National Institute for Health Development), Eva Ardanáz(Navarrabiomed), Magdalena Bielska‐Lasota(Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy), Susan Bolick(South Carolina Department of Health and Environmental Control), Rosemary D. Cress(Public Health Institute), Marloes A.G. Elferink(Netherlands Comprehensive Cancer Organisation), John P Fulton(Rhode Island Department of Health), Jaume Galcerán(Institut de Recerca Biomèdica Catalunya Sud), Stanisław Góźdż(Jan Kochanowski University), Timo Hakulinen(Finnish Cancer Registry), Maja Primic‐Žakelj(Institute of Oncology Ljubljana), Jadwiga Rachtan(The Maria Sklodowska-Curie National Research Institute of Oncology), C. Safaei Diba(National Health Information Center), María‐José Sánchez(Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública), Maria J. Schymura(New York State Department of Health), Tiefu Shen(Illinois Department of Public Health), Giovanna Tagliabue(Fondazione IRCCS Istituto Nazionale dei Tumori), ­Rosario ­Tumino(Azienda Usl 8 Arezzo), Marina Vercelli(Ospedale Policlinico San Martino), Holly J. Wolf(Colorado School of Public Health), Xiao‐Cheng Wu(Louisiana State University Health Sciences Center New Orleans), Michel P. Coleman(Cancer Research UK)
BMJ Open
September 10, 2013
Cited by 92Open Access
Full Text

Abstract

OBJECTIVES: To assess the extent to which stage at diagnosis and adherence to treatment guidelines may explain the persistent differences in colorectal cancer survival between the USA and Europe. DESIGN: A high-resolution study using detailed clinical data on Dukes' stage, diagnostic procedures, treatment and follow-up, collected directly from medical records by trained abstractors under a single protocol, with standardised quality control and central statistical analysis. SETTING AND PARTICIPANTS: 21 population-based registries in seven US states and nine European countries provided data for random samples comprising 12 523 adults (15-99 years) diagnosed with colorectal cancer during 1996-1998. OUTCOME MEASURES: Logistic regression models were used to compare adherence to 'standard care' in the USA and Europe. Net survival and excess risk of death were estimated with flexible parametric models. RESULTS: The proportion of Dukes' A and B tumours was similar in the USA and Europe, while that of Dukes' C was more frequent in the USA (38% vs 21%) and of Dukes' D more frequent in Europe (22% vs 10%). Resection with curative intent was more frequent in the USA (85% vs 75%). Elderly patients (75-99 years) were 70-90% less likely to receive radiotherapy and chemotherapy. Age-standardised 5-year net survival was similar in the USA (58%) and Northern and Western Europe (54-56%) and lowest in Eastern Europe (42%). The mean excess hazard up to 5 years after diagnosis was highest in Eastern Europe, especially among elderly patients and those with Dukes' D tumours. CONCLUSIONS: The wide differences in colorectal cancer survival between Europe and the USA in the late 1990s are probably attributable to earlier stage and more extensive use of surgery and adjuvant treatment in the USA. Elderly patients with colorectal cancer received surgery, chemotherapy or radiotherapy less often than younger patients, despite evidence that they could also have benefited.


Related Papers

No related papers found

Powered by citation graph analysis